Allergy Therapeutics (AGY) — Cash Flow-to-Debt Ratio
Allergy Therapeutics (AGY) has a Cash Flow-to-Debt Ratio of -0.18x as of December 2025, meaning its operating cash flow of GBX-11.71 Million could theoretically repay 0% of its total liabilities (GBX66.75 Million) in one year. See Allergy Therapeutics (AGY) flexibility index to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Allergy Therapeutics Cash Flow-to-Debt Ratio (2002–2025)
Historical debt coverage capacity for Allergy Therapeutics across 24 annual periods. For the full cash flow conversion analysis, see Allergy Therapeutics (AGY) cash flow conversion.
Annual Cash Flow-to-Debt Ratio for Allergy Therapeutics (2002–2025)
Year-by-year debt coverage analysis for Allergy Therapeutics. Check Allergy Therapeutics (AGY) cash earnings ratio to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (GBX) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.30x | GBX-28.72 Million | GBX95.74 Million | ▲ +43.0% |
| 2024 | -0.53x | GBX-32.14 Million | GBX61.12 Million | ▼ -10.1% |
| 2023 | -0.48x | GBX-30.92 Million | GBX64.70 Million | ▼ -19.1% |
| 2022 | -0.40x | GBX-14.11 Million | GBX35.18 Million | ▼ -286.3% |
| 2021 | 0.22x | GBX8.52 Million | GBX39.55 Million | ▼ -25.6% |
| 2020 | 0.29x | GBX12.28 Million | GBX42.44 Million | ▲ +59.8% |
| 2019 | 0.18x | GBX5.60 Million | GBX30.94 Million | ▲ +233.2% |
| 2018 | -0.14x | GBX-3.80 Million | GBX27.98 Million | ▼ -2177.6% |
| 2017 | 0.01x | GBX178.00K | GBX27.22 Million | ▲ +101.5% |
| 2016 | -0.45x | GBX-11.84 Million | GBX26.36 Million | ▼ -333.5% |
| 2015 | 0.19x | GBX3.12 Million | GBX16.23 Million | ▲ +18.0% |
| 2014 | 0.16x | GBX2.17 Million | GBX13.32 Million | ▼ -4.1% |
| 2013 | 0.17x | GBX2.43 Million | GBX14.29 Million | ▼ -22.2% |
| 2012 | 0.22x | GBX2.88 Million | GBX13.16 Million | ▲ +407.5% |
| 2011 | -0.07x | GBX-2.03 Million | GBX28.48 Million | ▼ -205.5% |
| 2010 | 0.07x | GBX1.70 Million | GBX25.23 Million | ▲ +793.8% |
| 2009 | -0.01x | GBX-440.00K | GBX45.25 Million | ▲ +98.3% |
| 2008 | -0.56x | GBX-19.32 Million | GBX34.47 Million | ▲ +54.3% |
| 2007 | -1.23x | GBX-18.88 Million | GBX15.40 Million | ▲ +21.7% |
| 2006 | -1.56x | GBX-8.10 Million | GBX5.18 Million | ▼ -17953.9% |
| 2005 | -0.01x | GBX-57.00K | GBX6.58 Million | ▼ -101.9% |
| 2004 | 0.46x | GBX1.91 Million | GBX4.16 Million | ▲ +22.6% |
| 2003 | 0.37x | GBX2.10 Million | GBX5.60 Million | ▲ +362.1% |
| 2002 | -0.14x | GBX-2.01 Million | GBX14.07 Million | — |